http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0210768-A9
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_93128ae21cb6e625a69403d6d42fe588 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e0ea14ed5c0b285255ea20dc99f57b4 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-8139 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5005 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
filingDate | 2001-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef40260d48f684c649ff36338bb7fa93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a02b840830c839b1dbf716e33ef79e3 |
publicationDate | 2003-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-0210768-A9 |
titleOfInvention | Model for alzheimer's disease and other neurodegenerative diseases |
abstract | The present invention provides a model for studying the development of, and/or pathologies associated with neurodegenerative diseases, and agents that can alter such development and/or pathologies. The model of the invention is especially useful as an Alzheimer's disease model. The model of the invention provides brain cells and a method for increasing neurodegenerative disease characteristics in such cells, especially, introductino of neurofibrillary tangles and/or phosphorylated tau and/or tau fragments and/or the production and/or release of cytokines and/or microglia reactions and/or activations and/or inflammation and/or conversion of p35 to p25 and/or the levels and activities of protein kinases by selectively increasing the concentration of cathepsin D to an effective level, and/or by lowering the concentration of cholesterol in such cells. The model also provides a method of reversing such effects, by inhibiting cysteine protease and mitogen-activated kinase activity, and especially, by inhibiting calpain, and/or MAP kinase. |
priorityDate | 2000-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 713.